ALKERMES SHARES UP 2.9% PREMARKET AFTER US FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION FOR ITS SLEEP DISORDER TREATMENT

Reuters · 2d ago

Please log in to view news